1,000
Participants
Start Date
April 10, 2023
Primary Completion Date
August 31, 2026
Study Completion Date
August 31, 2026
DB-1310
Administered I.V.
Trastuzumab
Administered I.V.
Osimertinib
Oral
RECRUITING
NEXT Virginia, Fairfax
RECRUITING
Research Site 111, Atlanta
RECRUITING
Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
RECRUITING
D&H Cancer Research Center LLC, Margate
RECRUITING
BRCR Medical Center Inc., Tamarac
RECRUITING
BRCR global, Plantation
RECRUITING
Florida Cancer Specialists, Sarasota
RECRUITING
Tennessee Oncology, PLLC, Nashville
RECRUITING
Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center, Cincinnati
RECRUITING
Henry Ford Health System, Detroit
RECRUITING
UCLA Hematology/Oncology - Santa Monica, Santa Monica
RECRUITING
University of California, Davis Comprehensive Cancer Center, Sacramento
RECRUITING
The First Hospital of China Medical University, Shenyang
RECRUITING
The first hospital of Jilin University, Changchun
RECRUITING
Shanghai Chest Hospital, Shanghai
RECRUITING
Jiangsu Province hospital, Nanjing
RECRUITING
Affiliated Hospital of Jiangnan University, Wuxi
RECRUITING
Hunan cancer hospital, Changsha
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
Sichuan Provincial People's Hospital, Chengdu
RECRUITING
Dana-Farber Cancer Institute, Boston
DualityBio Inc.
INDUSTRY